✦ LIBER ✦

Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer

✍ Scribed by Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Fujiwara, Yoshiro; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune

Book ID: 119319920
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 227 KB
Volume: 62
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2008.03.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib Monotherapy in Chemotherapy-Na

Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer

✍ Martin Reck; Erika Buchholz; Kathrin Schott-von-Römer; Katrin Krützfeldt; Ulrich 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 141 KB

The impact of epidermal growth factor re

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

✍ Shuji Ichihara; Shinichi Toyooka; Yoshiro Fujiwara; Katsuyuki Hotta; Hisayuki Sh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 403 KB 👁 2 views

## Abstract We investigated the relationships between genetic factors and clinical outcome in Japanese non‐small‐cell lung cancer (NSCLC) patients treated with gefitinib. Ninety‐eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor

Erlotinib after gefitinib failure in rel

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

✍ Hata, Akito; Katakami, Nobuyuki; Yoshioka, Hiroshige; Fujita, Shiro; Kunimasa, K 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 242 KB

A review of the benefit–risk profile of

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

✍ Park, Keunchil; Goto, Koichi 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 336 KB

Retrospective analysis of the predictive

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer

✍ Kaneda, Hiroyasu; Tamura, Kenji; Kurata, Takayasu; Uejima, Hisao; Nakagawa, Kazu 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 177 KB

Association between poor performance sta

Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience

✍ Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Suzuki, Etsuji; Yoshioka, H 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 132 KB